TEST:

DCISionRT

7-gene biosignature test resulted in a 35% reduction in patients treated with adjuvant RT. Patients with higher decision scores were more likely to receive RT and to receive a greater RT dose.

The 7-gene predictive DCIS biosignature more reliably identified patients with low 10-year IBR rates and no significant RT benefit than traditional CP factors as well as those with elevated long term IBR rates that benefited from RT with substantial crossover for low and high risk clinicopathologic patients, respectively. The use of DCISionRT allows for more personalized and accurate risk stratification, preventing the under- and over-treatment of patients with suspected "low-risk" or "high-risk" DCIS based on current clinicopathologic factors.

The 7-gene biosignature with RRt identified a subset of HER2(3+) patients with greater IBR rates following BCS and RT beyond traditional clinical and pathologic features. Consideration of therapies to reduce these elevated IBR rates should be evaluated, including the incorporation of HER2-targeted therapy.

P=NA | N=NA | "Prelude Corporation...announced results of a cutting-edge study in Clinical Breast Cancer....The study evaluated HER2-positive patients treated with breast conserving surgery (BCS) plus radiation therapy (RT) to determine if the DCISionRT test could identify those patients with elevated residual risk remaining after treatment. The study showed that patients with the DCISionRT Residual Risk subtype had significantly higher in-breast recurrence (IBR) rates compared to those without the Residual Risk subtype (16.2% vs 1.6%, p=.01)....DCISionRT successfully identified two distinct groups of HER2(3+) DCIS patients treated with breast-conserving surgery (BCS) plus radiation therapy (RT) that could not be identified using traditional clinicopathologic factors."

P=N/A, N=3000, Recruiting, PreludeDx | Suspended --> Recruiting

In conclusion, Reddit is an invaluable community for breast cancer survivors and reflects the necessity of support groups. Our study demonstrates the importance of continuing support groups centered on providing a safe space to seek advice, vent, and find solidarity. It also stresses the demand for more education and workshops on coping, treatment decision-making, and understanding diagnoses and prognoses.

"Prelude Corporation...and Cancer Help Desk, have partnered to provide expert nurse navigation services for women diagnosed with ductal carcinoma in situ (DCIS) breast cancer. This alliance allows for direct engagement between newly diagnosed DCIS patients seeking assistance with clinical options and healthcare professionals trained in breast cancer patient navigation....This novel collaboration within the diagnostic laboratory testing space demonstrates a shared commitment to empowering patients with tools needed to inform their treatment decision-making and planning processes."

"Prelude Corporation...announced an important advancement in the field of breast cancer care with the publication of the PREDICT study in the Annals of Surgical Oncology (ASO)....Significant impact on treatment decisions: DCISionRT test results led to a change in pre-test to post-test RT recommendations for 38% of women, highlighting its clinical utility in optimizing treatment plans based on individual patient risk profiles. Net reduction in RT recommendations: Overall, the test contributed to a 20% net reduction in the number of women recommended for RT, potentially sparing many from unnecessary treatment and associated side effects."

P=N/A; The test results provided information that changes treatment recommendations both for and against RT use in large population of women with DCIS treated in a variety of clinical settings. Overall, clinicians changed their recommendations to include or omit RT for 38% of women based on the test results. Based on published clinical validations and the results from current study, DCISionRT may aid in preventing the over- and undertreatment of clinicopathological 'low-risk' and 'high-risk' DCIS patients.

"Prelude Corporation...announced that it will share data demonstrating the power of its DCISionRT test to better predict radiation therapy (RT) benefit in comparison to clinicopathologic risk factors for women with ductal carcinoma in situ (DCIS) at The American Society of Clinical Oncology (ASCO), to be held on May 31 – June 4, 2024 at the McCormick Place in Chicago....Of particular importance, the DCISionRT biosignature identified a low-risk group of patients with no significant benefit from ET or RT after breast-conserving surgery."

In our study, radiologic distribution did not correlate with DCISionRT risk subtypes. A larger tumor size, more advanced histologic grade, and advanced patient age correlated with DCISionRT subtypes of an elevated or residual risk. This study uses a genomic risk assessment tool as a surrogate for identifying lesions with a high recurrence risk.